RECURRENT ESOPHAGEAL CARCINOMA
Clinical trials for RECURRENT ESOPHAGEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ESOPHAGEAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ESOPHAGEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising combo targets Hard-to-Treat esophageal cancer
Disease control OngoingThis study tests whether adding the drug cixutumumab to standard chemotherapy (paclitaxel) can help people with advanced esophageal or stomach-junction cancer live longer without their cancer growing. About 94 adults whose cancer has spread and who have already tried one treatmen…
Matched conditions: RECURRENT ESOPHAGEAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 06:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Matched conditions: RECURRENT ESOPHAGEAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 06:00 UTC